Bibliographic information
GuidelineWHO recommendations on maternal and newborn care for a positive postnatal experience.
Year of Publication2022
Issuing InstitutionWorld Health Organization
Recommendation
Maintained
In endemic communities with Schistosoma spp. prevalence of less than 10%, WHO suggests one of two approaches based on the programmes’ objectives and resources: (i) where there has been a programme of regular preventive chemotherapy, continuing preventive chemotherapy at the same or a reduced frequency towards interruption of transmission; and (ii) where there has not been a programme of regular preventive chemotherapy, a clinical approach of test-and-treat, instead of preventive chemotherapy targeting a population.
Context specific recommendation
Only in specific contexts
Certainty of evidence
Low
Notes and Remarks
Remarks
- These recommendations have been adapted and integrated from the 2022 WHO guideline on control and elimination of human schistosomiasis (84). Recommendation 16a for settings with prevalence above 10% was considered a strong recommendation based on moderate-certainty evidence. Recommendation 16b was considered a conditional recommendation based on low to very low-certainty evidence.
- The source guideline notes that, in endemic communities with Schistosoma spp. baseline prevalence of 10% or higher that demonstrate a lack of appropriate response to annual preventive chemotherapy despite adequate coverage (≥ 75%), WHO suggests biannual instead of annual preventive chemotherapy, in coordination with the interventions stated in Recommendation 3: Conditional recommendation (very lowcertainty evidence).
Also Featured In
This recommendation also appears in the following guidelines:
Originally Developed
Guideline
WHO guideline on control and elimination of human schistosomiasis.
Year2022
InstitutionWHO